An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
Open Access
- 1 January 2009
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 8 (1) , 115
Abstract
MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments.Keywords
This publication has 45 references indexed in Scilit:
- Targeting the MDM2-p53 Interaction for Cancer TherapyClinical Cancer Research, 2008
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2007
- Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patientsCancer, 2007
- Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer CenterJournal of Clinical Oncology, 2006
- Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivoMolecular Cancer Therapeutics, 2006
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993